BioMed X has announced the launch of its first research team at its newly established France site, marking its entry into one of Europe’s rapidly growing life sciences ecosystems. The initiative strengthens the organisation’s global research footprint and expands its focus on cutting-edge biomedical innovation.

The newly formed Team ADB (AI-Empowered Design of Bispecific Antibodies) is based at the XSeed Labs incubator on the R&D campus of Servier in Paris-Saclay. The team operates within the Spartners facility, a collaborative environment jointly run by Servier and BioLabs.

The research programme will focus on advancing bispecific antibodies—an emerging class of biologic therapies capable of targeting two different molecules simultaneously. These therapies hold significant promise across areas such as cancer and immune-related disorders but remain complex to engineer due to challenges in structural stability, dual-target interaction, and manufacturability.

The team is led by Tomabu Adjobimey, an immunologist with experience in immune system modulation and host-pathogen interactions. The project aims to develop an artificial intelligence-driven platform that combines structural modelling, machine learning and laboratory validation to improve the predictability and efficiency of antibody design.

Paula Wagner Egea, Managing Director and Site Head of BioMed X France, said the initiative reflects the organisation’s commitment to interdisciplinary research at the intersection of AI and life sciences. She highlighted that the collaboration aims to accelerate innovation in immuno-oncology and other therapeutic areas.

Clément Barjon from Servier noted that while bispecific antibodies are becoming a key modality in modern oncology, their development remains highly complex. The collaboration is expected to address these challenges through a more systematic and technology-driven approach.

BioMed X operates as a global innovation platform, connecting academic research with pharmaceutical industry needs. The launch of its France-based team is expected to contribute to faster discovery and development of next-generation biologic therapies.